Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VOICE: COVID-19 Vaccination in Cancer Patients
NCT04715438Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Jan 2021
- Primary completion
- Jun 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Open-label trial of elasomeran in coronavirus disease 2019 (COVID-19) (4 cohorts), sponsored by University Medical Center Groningen. Primary endpoint: Immune response to vaccination against COVID-19 measured as antibody response. Started Jan 2021; status: active, not recruiting.
02
Drugs
elasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04715438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04715438.